Fraser Wright, the co-founder of Spark Therapeutics Inc, has joined the scientific advisory board of CEVEC Pharmaceuticals GmbH, which produces viral vectors for gene therapy. Dr Wright is chief technology officer for gene therapies at Axovant Sciences Inc. He was previously head of technology at Spark where he oversaw the development of Luxturna (voretigene neparvovec-rzyl), the first gene therapy to be approved by the US Food and Drug Administration for patients with an inherited retinal disease. He received his BSc and PhD in biochemistry from the University of Toronto, Canada where he was also an assistant professor of biochemistry and medicine.
CEVEC announced the appointment on 28 June 2018.
Evernow Publishing Ltd 2018.